Why uniQure shares are sinking after AMT-130 update

Economic Times - Sep 30, 2026

uniQure shares plunged after four-year data for Huntington’s gene therapy AMT-130 showed weaker disease-progression slowing than earlier results. While 48-month TFC data remained encouraging, the cUHDRS effect was not statistically significant. Investors are now focused on FDA review and whether the therapy’s earlier benefits can demonstrate durability over time.

Read full article
More News
Copyright © 2015 - 2026 The Financial Capital.

All Rights Reserved.

Subscribe Now!

About Us

The Financial Capital is your independent source for finance information and advice. We provide insights and offer advice from financial experts so you can make the best decisions.